TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
University of Kentucky researchers reported that mice with Alzheimer’s-like changes slept more than two additional hours a day after most of their microglia were temporarily removed. The intervention did not clear amyloid plaques, and the results are from mice, so they do not establish a safe or effective treatment for people.
Researchers at the University of Kentucky reported that mice with Alzheimer’s-like brain changes slept more than two additional hours per day after scientists temporarily depleted most of their microglia, the brain’s immune cells. The improvement occurred without clearing amyloid plaques, according to the study published in Alzheimer’s & Dementia; it is an animal finding, not evidence that the approach will treat sleep problems in people with Alzheimer’s.
The team gave the mice pexidartinib, also called PLX3397, in their food for 14 days. The drug blocks a signal microglia need to survive. After treatment, the researchers measured an approximately 87% reduction in microglia. They then found that the Alzheimer’s-model mice slept longer and spent more time in deep sleep. The report says the sleep increase exceeded two hours per day.
To track sleep, researchers used devices recording electroencephalography (EEG) and electromyography (EMG), which capture electrical activity in the brain and muscles. The team also used light-sheet microscopy to map plaques and microglia in the brain. The experiments included genetically modified mice that develop amyloid plaques and normally aging mice, examined at six and 18 months.
The findings were reported by a team led by Shannon L. Macauley, an associate professor of physiology at the university’s College of Medicine. First author Nicholas J. Constantino recently completed his doctorate. The supplied report describes the sleep result and the degree of microglia depletion, but does not provide further numerical details about the study’s size or the precise sleep-stage changes.
Microglia May Link Plaques and Sleep Loss
The study points to a possible explanation for why sleep can be disrupted alongside Alzheimer’s pathology: the brain’s immune response to plaques may contribute to the problem, rather than plaques or injured neurons acting alone. If that mechanism also operates in people, it could widen research into sleep symptoms beyond approaches aimed at removing amyloid. The current evidence, however, supports a research hypothesis, not a clinical treatment.
Sleep difficulties can add to the burden experienced by people with Alzheimer’s and their caregivers. A finding that sleep improved while plaques remained in these mice suggests that symptom-related brain processes might be separable from plaque removal. But the experiment does not show that reducing microglia would be safe, practical, or beneficial in humans. Microglia also perform protective functions, so removing most of them is not a simple therapeutic proposal.
EEG sleep monitor for home sleep tracking
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How the Mouse Experiment Was Set Up
Microglia are resident immune cells that help clear debris, respond to injury and maintain the brain’s environment. In Alzheimer’s, amyloid plaques are a characteristic feature of disease pathology. The researchers propose that microglia responding to plaques can release inflammatory signals that interfere with normal sleep regulation. That account shifts attention toward the inflammatory response around plaques, while not establishing that plaques themselves have no role.
The investigators compared a genetically predisposed mouse group with wild-type mice that underwent typical aging. Measurements at six months, when plaques first appeared in the model, and at 18 months, when pathology was more advanced, allowed the team to examine changes across age and disease-like progression. The drug intervention then tested whether reducing microglia changed sleep. These controlled animal experiments can identify mechanisms for further study, but mouse results do not directly predict human outcomes.
“Basically, we showed that it is not the plaques themselves, or solely dysfunctional neurons, that cause sleep loss but actually microglia.”
— Shannon L. Macauley, University of Kentucky
Human Benefits and Risks Remain Unknown
The study was conducted in mice with Alzheimer’s-like changes, not people with Alzheimer’s disease. The supplied report does not establish whether the same microglial process causes sleep loss in humans, whether the sleep effect would persist, or whether a comparable intervention could be used safely. It also does not report whether the treatment changed memory, disease progression or other health outcomes.
Microglia have roles in normal brain maintenance and defense. The experiment’s approximately 87% depletion was temporary and produced with a drug developed in a cancer-research context; the report does not establish that this degree of reduction is appropriate for people. The exact study size, the full duration of follow-up and detailed measurements underlying the reported sleep gain are not given in the source material. The findings should not be treated as medical advice or as evidence that patients should seek or use pexidartinib for sleep.
Further Studies Must Test the Mechanism
The immediate next step is further research to establish how microglia-related inflammation affects sleep and whether the effect can be altered without undermining the cells’ protective functions. Researchers would also need to determine how durable the sleep improvement is and whether it comes with changes to other Alzheimer’s-related outcomes. The report does not announce a human trial or provide a timetable for one.
Any move toward testing a treatment in people would require evidence on safety, dosing and likely benefit, followed by appropriately designed clinical studies. Until such evidence is available, the result is best understood as a preclinical finding that identifies a possible contributor to sleep loss, rather than a breakthrough treatment for patients.
Key Questions
What did the researchers find?
In an Alzheimer’s mouse model, sleep increased by more than two hours per day after researchers temporarily depleted most microglia. The study reported that the improvement occurred without clearing amyloid plaques.
What are microglia?
Microglia are immune cells in the brain that help remove debris, respond to injury and maintain the environment around nerve cells. The researchers propose that their inflammatory response to plaques may interfere with sleep in the mouse model.
Was the result demonstrated in people?
No. The reported experiments were conducted in mice. The findings do not establish that microglia depletion would improve sleep or be safe for people with Alzheimer’s.
Did the treatment remove amyloid plaques?
No. According to the report, the mice slept longer without the plaques being cleared. The study therefore points to a possible sleep mechanism distinct from plaque removal.
Does this mean patients should take pexidartinib for sleep?
No. The study does not establish pexidartinib as a sleep treatment or recommend its use for Alzheimer’s. People should consult a qualified health professional about medical decisions.
Source: hn
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
